Ivonescimab reportedly improves overall survival over pembrolizumab in advanced lung cancer
A science and health roundup highlights the reported survival benefit alongside other lung cancer results, including a combination therapy that missed its endpoints.
TLDR
A science and health roundup says ivonescimab improved overall survival compared with pembrolizumab in advanced lung cancer. It also highlights other lung cancer trial readouts, noting that one combination therapy missed its endpoints.
Combined views
320
1 Source, first seen ago